Abstract

AMH has been recognized as a useful diagnostic and prognostic tool as a reliable marker of ovarian reserve and predictor of ovarian response to controlled ovarian hyperstimulation. AMH is a member of the transforming growth factor β (TGF-β) superfamily and may be more elevated in endometriosis patients (1) as these growth factors are involved the inflammatory cascade incited by endometriotic lesions. We sought to determine whether AMH levels overestimate actual ovarian response in patients with endometriosis given that AMH is more likely to be elevated in these patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.